Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

First-in-human study investigates HJV inhibitor DISC-0974 for anemia of inflammation

July 28, 2021

FXa-DOAC reversal with no thrombogenic potential seen with VMX-C001

July 28, 2021

ExCellThera initiates phase I study of ECT-001-CB in sickle cell disease

July 23, 2021

Chinese researchers patent coagulation factor XIa inhibitors

July 23, 2021

FDA places clinical hold on phase I/II study of SIG-001 in hemophilia A

July 12, 2021

FDA clears IND for ASC-618 gene therapy for hemophilia A

July 8, 2021

Shenzhen Salubris Pharmaceuticals patents factor XIa inhibitors

June 30, 2021

Keros reports preliminary phase II data on KER-050 for MDS

June 23, 2021

Etavopivat improves hematologic and hemolytic parameters in patients with sickle cell disease

June 21, 2021

Shenzhen Salubris Pharmaceuticals synthesizes FXIa inhibitors

June 16, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...